Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma

Valeria Magarotto, S. Bringhen, Massimo Offidani, Giulia Benevolo, F. Patriarca, Roberto Mina, Antonietta Pia Falcone, Lorenzo De Paoli, Giuseppe Pietrantuono, Silvia Gentili, Caterina Musolino, Nicola Giuliani, Annalisa Bernardini, C. Conticello, Stefano Pulini, G. Ciccone, Vladimír Maisnar, M. Ruggeri, R. Zambello, Tommasina GuglielmelliAntonio Ledda, A. M. Liberati, Vittorio Montefusco, Roman Hajek, M. Boccadoro, A. Palumbo

Research output: Contribution to journalArticle

Abstract

Lenalidomide-dexamethasone improved outcome in newly diagnosed elderly multiple myeloma patients. We randomly assigned 662 patients who were age ≥65 years or transplantation-ineligible to receive induction with melphalan-prednisone-lenalidomide (MPR) or cyclophosphamide-prednisone-lenalidomide (CPR) or lenalidomide plus lowdose dexamethasone (Rd). The primary end point was progression-free survival (PFS) in triplet (MPR and CPR) vs doublet (Rd) lenalidomide-containing regimens. After a median follow-up of 39 months, the medianPFSwas22 months for the triplet combinations and 21 months for the doublet (P =.284). The median overall survival (OS) was not reached in either arms, and the 4-year OS was 67% for the triplet and 58% for the doublet arms (P =.709). By considering the 3 treatment arms separately, no difference in outcome was detected among MPR, CPR, and Rd. The most common grade ≥3 toxicity was neutropenia: 64% in MPR, 29% in CPR, and 25% in Rd patients (P

Original languageEnglish
Pages (from-to)1102-1108
Number of pages7
JournalBlood
Volume127
Issue number9
DOIs
Publication statusPublished - Mar 3 2016

Fingerprint

Multiple Myeloma
Prednisone
Melphalan
Cyclophosphamide
Therapeutics
Dexamethasone
lenalidomide
Survival
Neutropenia
Disease-Free Survival
Toxicity
Transplantation

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Magarotto, V., Bringhen, S., Offidani, M., Benevolo, G., Patriarca, F., Mina, R., ... Palumbo, A. (2016). Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood, 127(9), 1102-1108. https://doi.org/10.1182/blood-2015-08-662627

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. / Magarotto, Valeria; Bringhen, S.; Offidani, Massimo; Benevolo, Giulia; Patriarca, F.; Mina, Roberto; Falcone, Antonietta Pia; De Paoli, Lorenzo; Pietrantuono, Giuseppe; Gentili, Silvia; Musolino, Caterina; Giuliani, Nicola; Bernardini, Annalisa; Conticello, C.; Pulini, Stefano; Ciccone, G.; Maisnar, Vladimír; Ruggeri, M.; Zambello, R.; Guglielmelli, Tommasina; Ledda, Antonio; Liberati, A. M.; Montefusco, Vittorio; Hajek, Roman; Boccadoro, M.; Palumbo, A.

In: Blood, Vol. 127, No. 9, 03.03.2016, p. 1102-1108.

Research output: Contribution to journalArticle

Magarotto, V, Bringhen, S, Offidani, M, Benevolo, G, Patriarca, F, Mina, R, Falcone, AP, De Paoli, L, Pietrantuono, G, Gentili, S, Musolino, C, Giuliani, N, Bernardini, A, Conticello, C, Pulini, S, Ciccone, G, Maisnar, V, Ruggeri, M, Zambello, R, Guglielmelli, T, Ledda, A, Liberati, AM, Montefusco, V, Hajek, R, Boccadoro, M & Palumbo, A 2016, 'Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma', Blood, vol. 127, no. 9, pp. 1102-1108. https://doi.org/10.1182/blood-2015-08-662627
Magarotto, Valeria ; Bringhen, S. ; Offidani, Massimo ; Benevolo, Giulia ; Patriarca, F. ; Mina, Roberto ; Falcone, Antonietta Pia ; De Paoli, Lorenzo ; Pietrantuono, Giuseppe ; Gentili, Silvia ; Musolino, Caterina ; Giuliani, Nicola ; Bernardini, Annalisa ; Conticello, C. ; Pulini, Stefano ; Ciccone, G. ; Maisnar, Vladimír ; Ruggeri, M. ; Zambello, R. ; Guglielmelli, Tommasina ; Ledda, Antonio ; Liberati, A. M. ; Montefusco, Vittorio ; Hajek, Roman ; Boccadoro, M. ; Palumbo, A. / Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. In: Blood. 2016 ; Vol. 127, No. 9. pp. 1102-1108.
@article{0222b1094c7f4dc495d20a115b4f3744,
title = "Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma",
abstract = "Lenalidomide-dexamethasone improved outcome in newly diagnosed elderly multiple myeloma patients. We randomly assigned 662 patients who were age ≥65 years or transplantation-ineligible to receive induction with melphalan-prednisone-lenalidomide (MPR) or cyclophosphamide-prednisone-lenalidomide (CPR) or lenalidomide plus lowdose dexamethasone (Rd). The primary end point was progression-free survival (PFS) in triplet (MPR and CPR) vs doublet (Rd) lenalidomide-containing regimens. After a median follow-up of 39 months, the medianPFSwas22 months for the triplet combinations and 21 months for the doublet (P =.284). The median overall survival (OS) was not reached in either arms, and the 4-year OS was 67{\%} for the triplet and 58{\%} for the doublet arms (P =.709). By considering the 3 treatment arms separately, no difference in outcome was detected among MPR, CPR, and Rd. The most common grade ≥3 toxicity was neutropenia: 64{\%} in MPR, 29{\%} in CPR, and 25{\%} in Rd patients (P",
author = "Valeria Magarotto and S. Bringhen and Massimo Offidani and Giulia Benevolo and F. Patriarca and Roberto Mina and Falcone, {Antonietta Pia} and {De Paoli}, Lorenzo and Giuseppe Pietrantuono and Silvia Gentili and Caterina Musolino and Nicola Giuliani and Annalisa Bernardini and C. Conticello and Stefano Pulini and G. Ciccone and Vladim{\'i}r Maisnar and M. Ruggeri and R. Zambello and Tommasina Guglielmelli and Antonio Ledda and Liberati, {A. M.} and Vittorio Montefusco and Roman Hajek and M. Boccadoro and A. Palumbo",
year = "2016",
month = "3",
day = "3",
doi = "10.1182/blood-2015-08-662627",
language = "English",
volume = "127",
pages = "1102--1108",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma

AU - Magarotto, Valeria

AU - Bringhen, S.

AU - Offidani, Massimo

AU - Benevolo, Giulia

AU - Patriarca, F.

AU - Mina, Roberto

AU - Falcone, Antonietta Pia

AU - De Paoli, Lorenzo

AU - Pietrantuono, Giuseppe

AU - Gentili, Silvia

AU - Musolino, Caterina

AU - Giuliani, Nicola

AU - Bernardini, Annalisa

AU - Conticello, C.

AU - Pulini, Stefano

AU - Ciccone, G.

AU - Maisnar, Vladimír

AU - Ruggeri, M.

AU - Zambello, R.

AU - Guglielmelli, Tommasina

AU - Ledda, Antonio

AU - Liberati, A. M.

AU - Montefusco, Vittorio

AU - Hajek, Roman

AU - Boccadoro, M.

AU - Palumbo, A.

PY - 2016/3/3

Y1 - 2016/3/3

N2 - Lenalidomide-dexamethasone improved outcome in newly diagnosed elderly multiple myeloma patients. We randomly assigned 662 patients who were age ≥65 years or transplantation-ineligible to receive induction with melphalan-prednisone-lenalidomide (MPR) or cyclophosphamide-prednisone-lenalidomide (CPR) or lenalidomide plus lowdose dexamethasone (Rd). The primary end point was progression-free survival (PFS) in triplet (MPR and CPR) vs doublet (Rd) lenalidomide-containing regimens. After a median follow-up of 39 months, the medianPFSwas22 months for the triplet combinations and 21 months for the doublet (P =.284). The median overall survival (OS) was not reached in either arms, and the 4-year OS was 67% for the triplet and 58% for the doublet arms (P =.709). By considering the 3 treatment arms separately, no difference in outcome was detected among MPR, CPR, and Rd. The most common grade ≥3 toxicity was neutropenia: 64% in MPR, 29% in CPR, and 25% in Rd patients (P

AB - Lenalidomide-dexamethasone improved outcome in newly diagnosed elderly multiple myeloma patients. We randomly assigned 662 patients who were age ≥65 years or transplantation-ineligible to receive induction with melphalan-prednisone-lenalidomide (MPR) or cyclophosphamide-prednisone-lenalidomide (CPR) or lenalidomide plus lowdose dexamethasone (Rd). The primary end point was progression-free survival (PFS) in triplet (MPR and CPR) vs doublet (Rd) lenalidomide-containing regimens. After a median follow-up of 39 months, the medianPFSwas22 months for the triplet combinations and 21 months for the doublet (P =.284). The median overall survival (OS) was not reached in either arms, and the 4-year OS was 67% for the triplet and 58% for the doublet arms (P =.709). By considering the 3 treatment arms separately, no difference in outcome was detected among MPR, CPR, and Rd. The most common grade ≥3 toxicity was neutropenia: 64% in MPR, 29% in CPR, and 25% in Rd patients (P

UR - http://www.scopus.com/inward/record.url?scp=84960375377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960375377&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-08-662627

DO - 10.1182/blood-2015-08-662627

M3 - Article

VL - 127

SP - 1102

EP - 1108

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -